Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead to Present at Series of Upcoming Scientific Conferences: Data Highlights Results Demonstrating Effectiveness of DPC siRNA Delivery System and Path to the Clinic for siRNA-based Hepatitis B Treatment

Abstract:
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that senior management will present data for its Dynamic PolyConjugateTM (DPC) delivery platform for siRNA delivery including its RNAi therapeutic candidate for the treatment of hepatitis B virus (HBV) at several upcoming scientific conferences.

Arrowhead to Present at Series of Upcoming Scientific Conferences: Data Highlights Results Demonstrating Effectiveness of DPC siRNA Delivery System and Path to the Clinic for siRNA-based Hepatitis B Treatment

Pasadena, CA | Posted on May 3rd, 2012

"Arrowhead's DPC delivery system and the associated HBV program have been under development for several years at our Madison site, first as Mirus Bio and then as a subsidiary of Roche. It's been several years since data regarding the programs have been presented to the scientific community at large. We are looking forward to unveiling advanced and exciting results in these forums and to related publications later this year," said Dr. Christopher Anzalone, Arrowhead's CEO & President.

Scheduled conference presentations are as follows:

European Foundation for Clinical Nanomedicine (CLINAM)
Basel, Switzerland

An oral presentation titled, "DPC Technology for Safe and Effective siRNA Delivery," will be presented by Dr. David Lewis, Vice President, Biology and Site Head on May 9, 2012 at 8:35 AM CEST

TIDES: Oligonucleotide & PeptideŽ Research, Technology & Product Development

Las Vegas, NV, May 20-23

A poster titled, "Liver-targeted and reversibly masked-polycation co-delivery improves cholesterol-conjugated siRNA efficacy" will be presented by Dr. Darren Wakefield, Senior Scientist

RNA Society Annual Meeting
Ann Arbor, MI

A poster titled, "Effective RNAi Therapeutic to Treat Chronic Hepatitis B Virus Infection." will be presented by Dr. Christine Wooddell, Senior Scientist

RNAi Research & Therapeutics Conference

Boston, MA, May 29-June 3

An oral presentation titled, "The Development of Dynamic Poly Conjugates" will be presented by Dr. David Rozema, Vice President, Chemistry, on May 30, 2012 at 10:30 AM ET

RNAi & Nanotechnology Conference

London, UK

An oral presentation titled, "DPC Technology for siRNA Delivery: from rodents to primates" will be presented by Dr. David Lewis on June 11, 2012 11:40 AM GMT

International Congress on Infectious Diseases

Bangkok, Thailand

An oral presentation in the session New Developments in Viral Diseases: "RNAi therapeutics for the treatment of chronic hepatitis B virus infection" will be presented by Dr. David Lewis on Friday, June 15, 2012, 3:45 PMICT

Arrowhead published a white paper providing an overview of its proprietary DPC technology for safe and effective delivery of siRNA. This white paper can be found on the Arrowhead website at www.arrowheadresearch.com/pdf/Arrowhead-Research-Corporation_-_DPC-Technology-White-Paper-November2011.pdf

Arrowhead has also released a white paper describing the health problem posed by the hepatitis B virus (HBV), the substantial unmet need for chronic HBV infected patients, and how Arrowhead's Dynamic Polyconjugate (DPC) enabled RNAi therapeutic in development could potentially address deficiencies of current treatment options. This white paper can be found on the Arrowhead website at www.arrowheadresearch.com/pdf/whitepaper-hbv-3-7-12.pdf

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and AdipotideTM, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugateTM (DPC), Liposomal Nanoparticle (LNP), and RONDELTM delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Investor Relations Contact:
Michael Levitan
The Trout Group, LLC
646-378-2920

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Nanomedicine

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Announcements

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Events/Classes

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

Stress-free ALD from Picosun August 28th, 2018

Kavli Lectures: New vision of nanomaterial synthesis and light-fueled space travel August 8th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project